Article Text

This article has a correction. Please see:

other Versions

PDF
Successful Use of Rituximab in a Patient with Churg-Strauss Syndrome and refractory CNS Involvement
  1. Jasemine Saech (jasemine.saech{at}uk-koeln.de)
  1. Med I, University clinic Cologne, Germany
    1. Kasia Owczarczyk (katarzyna.owczarczyk{at}uk-koeln.de)
    1. Med I, University clinic Cologne, Germany
      1. Silviya Roesgen
      1. Radiology, University Clinic Cologne, Germany
        1. H Petereit
        1. Neurology, Heilig-Geist Hospital Cologne, Germany
          1. Michael Hallek
          1. Med I, University clinic Cologne, Germany
            1. Andrea Rubbert
            1. Med I, University clinic Cologne, Germany

              Abstract

              Churg-Strauss-Syndrom (CSS) is a disorder characterized by pulmonary and systemic small-vessel vasculitis, extravascular granuloma and hypereosinophilia that occurs in patients with asthma and allergic rhinitis. The involvement of the central nervous system (CNS) is less common than peripheral neuropathy, but causes significant morbidity and mortality in affected patients.

              Systemic glucocorticoids in combination with cyclophosphamide represent the treatment of choice in patients with systemic involvement of heart, nervous system or kidney. In case of intolerance or failure to cyclophosphamide, plasma exchange, interferon alpha, or other immunosuppressants such as mycophenolat mofetil have been suggested as alternative treatment options.

              Recently, the successful use of rituximab (RTX) in patients with ANCA-associated vasculitis as an anti-CD20 directed B-cell depleting antibody was reported. However, only few case reports on the use of RTX in CSS are available, none of them including patients with CNS.

              Statistics from Altmetric.com

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

              Linked Articles

              • Miscellaneous
                BMJ Publishing Group Ltd and European League Against Rheumatism